Search Results

Your search for Mario E. Lacouture, MD matches 2 pages

Showing 1 - 2

By Matthew Stenger / Tuesday, July 2, 2019 3:59 PM

Treatment of Immune Checkpoint Inhibitor Immune-Related Cutaneous Adverse Events

In a study reported in the Journal of Clinical Oncology, Phillips et al found that immune-related cutaneous adverse events in patients receiving immune checkpoint inhibitors generally responded to symptom- and phenotype-directed dermatologic therapies, and that biologic therapies were effective in...

skin cancer

symptom management

By Mario E. Lacouture, MD / 2015 NCCN Annual Conference

Mario E. Lacouture, MD, on Management of Dermatologic Toxicities Associated With Targeted Therapies

Mario E. Lacouture, MD, of Memorial Sloan Kettering Cancer Center, discusses the effect on patients of dermatologic toxicities associated with targeted therapies: their psychosocial impact, financial burden, physiological pain, and potential to alter therapy. But the side effects of targeted...

Apr

Today In Oncology

Search Results

Your search for Mario E. Lacouture, MD matches 2 pages

Treatment of Immune Checkpoint Inhibitor Immune-Related Cutaneous Adverse Events

Mario E. Lacouture, MD, on Management of Dermatologic Toxicities Associated With Targeted Therapies

Adjuvant Pembrolizumab in Renal Cell Carcinoma: Overall Survival in KEYNOTE-564

Combined ICI and VEGF Inhibitor Trials in Cancer Cardiovascular Eligibility Criteria and Adverse Event Reporting

Risk of T-Cell and Second Primary Malignant Neoplasms After CAR T-Cell Therapy

Lack of Research Focused on Older Adults With Cancer May Be Contributing to Disparities in Care

Breast Cancer Survivors: Relationship Satisfaction and Emotional and Physical Well-Being